FAMOTIDINE AND IBUPROFEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Famotidine And Ibuprofen, and what generic alternatives are available?
Famotidine And Ibuprofen is a drug marketed by Torrent and is included in one NDA.
The generic ingredient in FAMOTIDINE AND IBUPROFEN is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Famotidine And Ibuprofen
A generic version of FAMOTIDINE AND IBUPROFEN was approved as famotidine; ibuprofen by ENDO OPERATIONS on March 22nd, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FAMOTIDINE AND IBUPROFEN?
- What are the global sales for FAMOTIDINE AND IBUPROFEN?
- What is Average Wholesale Price for FAMOTIDINE AND IBUPROFEN?
Summary for FAMOTIDINE AND IBUPROFEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 6 |
| DailyMed Link: | FAMOTIDINE AND IBUPROFEN at DailyMed |
Recent Clinical Trials for FAMOTIDINE AND IBUPROFEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Duke University | Phase 4 |
| Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 4 |
| Pediatric Rheumatology Collaborative Study Group | Phase 4 |
US Patents and Regulatory Information for FAMOTIDINE AND IBUPROFEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Torrent | FAMOTIDINE AND IBUPROFEN | famotidine; ibuprofen | TABLET;ORAL | 215925-001 | Mar 18, 2024 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
